logo (1).png
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
March 27, 2024 02:30 ET | Vidac Pharma Holding PLC
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
PlayMining and TEPCO Partner on Web3 Game PicTree
PlayMining GameFi Platform Launching New Game PicTrée Partnered with Japan’s Largest Electric Co. TEPCO Power Grid
March 21, 2024 04:16 ET | PlayMining
Global GameFi platform PlayMining to launch "GamifiedWork" Inspect-to-Earn game "PicTrée" in partnership with TEPCO PG, Japan's largest power company.
noco2 logo high res.png
noco-noco and Neogen Forge Strategic Partnership to Unleash X-SEPA™ Technology in India's Burgeoning Battery Market (Projected to Exceed US$16 Billion by 2031)
March 07, 2024 19:00 ET | NOCO-NOCO PTE. LTD.
Singapore, March 08, 2024 (GLOBE NEWSWIRE) --  Highlights: Neogen secured a 3-year marketing and distribution license for noco-noco's X-SEPA™ technology with the eventual objective to...
HIS Group Invests in REGENT Seagliders
REGENT Craft Announces Strategic Investment from H.I.S.
March 07, 2024 10:28 ET | REGENT
North Kingstown, RI, March 07, 2024 (GLOBE NEWSWIRE) -- REGENT, the manufacturer of all-electric seagliders for sustainable maritime mobility, today announced a strategic investment from H.I.S....
noco-noco Inc, Neogen Ionics Ltd, Rechargeable Battery Materials and Technology, #India #Japan #CleanEnergy
noco-noco and Neogen Forge Strategic Partnership to Unleash X-SEPA™ Technology in India's Burgeoning Battery Market (Projected to Exceed US$16billion by 2031)
March 07, 2024 10:04 ET | NOCO-NOCO PTE. LTD.
noco-noco and Neogen Forge Strategic Partnership to Unleash X-SEPA™ Technology in India's Burgeoning Battery Market (To Exceed US$16billion by 2031)
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
March 04, 2024 02:00 ET | Medigene AG
Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Arcutis logo.png
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
February 28, 2024 16:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
February 14, 2024 03:00 ET | Numab Therapeutics AG
NM49 is a multi-specific antibody identified through Numab’s proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosis Numab to receive...
CITELINE_LOGO_FULL COLOUR_RGB.png
Introducing Citeline’s TrialScope Disclose: Core Data
February 01, 2024 09:00 ET | Citeline
The new TrialScope Disclose: Core Data platform consolidates clinical trial disclosure for global registries, including ClinicalTrials.gov, CTIS and jRCT.
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
January 25, 2024 16:05 ET | Travere Therapeutics, Inc.
Travere Therapeutics has entered into an exclusive licensing agreement with Renalys Pharma to bring sparsentan to patients in Japan.